Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

43

Revenue 2017

Perjeta

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Perjeta was produced by Roche.

Roche's Perjeta launches in UK for early breast cancer

Roche's Perjeta launches in UK for early breast cancer Roche's Perjeta is now licensed for use in the UK as a treatment for early-stage breast cancer, a few weeks after the new indication was approved in Europe. ... Perjeta was already approved to treat previously-untreated advanced HER2-positive breast

European approval for Roche’s next-gen breast cancer drug

European approval for Roche’s next-gen breast cancer drug Perjeta now available in EU for use before surgery in early stage aggressive breast cancer.  . ... We are committed to making the Perjeta regimen available to appropriate patients in the EU as early as possible.”.

UK pharma rebate payment doubles in one year

UK pharma rebate payment doubles in one year First quarter repayment £138m higher than this time last year

Roche maintains dominance as leading cancer drugmaker

Roche maintains dominance as leading cancer drugmaker drugs such as its next-generation breast cancer drug Perjeta (pertuzumab). ... This was highlighted in England where last year the country's health technology assessor NICE said Perjeta was nearly double the price (at £90, 000) than it would consider

Roche adds kidney cancer to anti-PD-L1 programme

Roche adds kidney cancer to anti-PD-L1 programme Sales of the company's HER2-targeting drugs - Herceptin (trastuzumab) and follow-up therapies Perjeta (pertuzumab) and Kadcyla (trastuzumab emtansine) - grew 23% thanks to increased use of Herceptin and Perjeta in ... The growth of Perjeta - up 82% to

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...
PANDAS/PANS Awareness: A parent’s story
To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...
Iskra Reic
Leading AstraZeneca’s return to growth in Europe
PME talks to Iskra Reic, the company’s head of Europe and Canada...

Infographics